Future studies should validate the diagnostic potential of hub genes with significant expression differences, such as BAX, BECN1, MAVS, and BCL2, using larger CA cohorts with diverse clinical phenotypes (e.g., allergic vs. non-allergic asthma) and explore their therapeutic implications through in vitro and in vivo models, such as CRISPR-based gene editing or animal models of CA, to pave the way for personalized treatment strategies. This evidence concerns the gene BECN1 and allergic asthma.